At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Risk of Serious Adverse Events Associated With Tamsulosin Use in Older Adults With Advanced Chronic Kidney Disease: A Population-Based Cohort Study Research Protocol
In Brief
An observational study evaluating Tamsulosin for Chronic Kidney Disease (CKD). Completed, enrolled 14,000 participants across 1 site.
Detailed Summary
This is a population-based cohort study assessing whether initiating a higher dose of tamsulosin (0.8 mg/day) compared to a lower dose (0.4 mg/day) in older adults with advanced chronic kidney disease (CKD) (an estimated glomerular filtration rate (eGFR) \<45 mL/min per 1.73 m² but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 90-day risk of a composite outcome of all-cause hospitalization or all-cause emergency visits or all-cause mortality.
Study Details
Timeline
Interventions
The primary exposure of interest will be oral tamsulosin at a dose of 0.4 mg/day, representing the median dose in high-throughput computing analyses. For the primary comparison, oral tamsulosin at a dose of 0.4 mg/day will be chosen to reduce the influence of indication bias.